搜索优化
English
全部
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
搜索
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Inverse
4 小时
Ozempic And Other GLP-1s Show Promise With 42 Conditions — But There Are Still Big Risks
Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...
10 天
on MSN
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
2 天
on MSN
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Medical News Today
9 天
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
5 小时
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
HealthDay on MSN
9 天
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions ...
Becker's Hospital Review
1 天
GLP-1 drug approvals: A breakdown
Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.
来自MSN
9 天
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
IFLScience
10 天
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
8 天
on MSN
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
9 天
The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
19 小时
on MSN
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈